Status:

COMPLETED

Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage

Lead Sponsor:

US Department of Veterans Affairs

Conditions:

Spinal Cord Injury

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The annual incidence of colorectal cancer in the US during 2005 was approximately 150,000 cases and this neoplasm claimed 56,000 lives (American Cancer Society). Detection (and removal) of colonic pol...

Detailed Description

The annual incidence of colorectal cancer in the US during 2005 was approximately 150,000 cases and this neoplasm claimed 56,000 lives (American Cancer Society). Detection (and removal) of colonic pol...

Eligibility Criteria

Inclusion

  • 1\. SCI and able-bodied patients with clinical indication for a colonoscopic examination

Exclusion

  • Able-bodied patients with a GFR 50ml/min.
  • SCI and able-bodied patients who are not candidates for elective colonoscopy (i.e., those with recent myocardial infarction, terminal illness, etc.)
  • SCI and able-bodied patients who have a contraindication to PEG and/or ascorbic acid administration (i.e., those with colonic obstruction, etc.)
  • SCI and able-bodied patients who have a contraindication for magnesium citrate (i.e., those with poor renal function, class 2 or greater symptomatic heart failure, ascites)
  • SCI and able-bodied patients with a history of bradyarrhythmia, active coronary artery disease or asthma will also be excluded from receiving neostigmine/glycopyrrolate
  • Known hypersensitivity to neostigmine or glycopyrrolate
  • Potential for pregnancy. Women who are sexually active and of childbearing potential (i.e. not surgically sterile or at least 2 years postmenopausal) must have negative serum pregnancy test.)
  • Lactating/nursing females
  • SCI patients with known adverse reactions to per-rectal colonic lavage.
  • SCI patients with a serum sodium \<130 mM.

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2013

Estimated Enrollment :

360 Patients enrolled

Trial Details

Trial ID

NCT00745095

Start Date

March 1 2009

End Date

May 1 2013

Last Update

July 16 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

VA Medical Center, Bronx

The Bronx, New York, United States, 10468